Solid Biosciences (SLDB) announced a collaboration with Mayo Clinic seeking to advance a cutting-edge AAV gene therapy platform for the development of next-generation therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies with high unmet medical need and significant patient populations. Under the terms of the agreement, Mayo Clinic’s Windland Smith Rice Sudden Death Genomics Laboratory will provide Solid with an exclusive license to their Suppression and Replacement gene therapy platform. The collaboration will also provide Solid with an exclusive license to develop and commercialize six cardiac gene therapy programs developed using Mayo Clinic’s “Sup-Rep” platform. These programs will use Solid’s next-generation AAV capsids, including AAV-SLB101, and advanced manufacturing capabilities to suppress and replace genes implicated in potentially life-threatening genetic heart diseases. Mayo Clinic will be responsible for research and development efforts for each cardiac gene therapy candidate up to IND-enabling studies, at which point, Solid will have the option to pursue continued development and commercialization of each licensed program.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLDB:
- Solid Biosciences reports inducement grant under Nasdaq listing rule
- Solid Biosciences Reports Increased Losses Amid R&D Focus
- Solid Biosciences price target lowered to $12 from $15 at JPMorgan
- Solid Biosciences to participates in a conference call hosted by JPMorgan
- Solid Biosciences reports Q3 EPS (79c), consensus (67c)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
